SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jul 11, 2019
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: July 11, 2019 · CIK: 0001430306 · Accession: 0001387131-19-004989
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232195
Letter
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, New York 10022
July 11, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 (File No. 333-232195)
Ladies and Gentlemen:
Tonix Pharmaceuticals Holding Corp. hereby requests that its acceleration request dated July 9, 2019 be withdrawn.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 with any questions.
Very truly yours,
TONIX PHARMACEUTICALS HOLDINGS
CORP.
Show Raw Text
CORRESP
1
filename1.htm
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, New York 10022
July
11, 2019
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re: Tonix
Pharmaceuticals Holding Corp.
Registration Statement on Form S-1 (File No. 333-232195)
Ladies
and Gentlemen:
Tonix
Pharmaceuticals Holding Corp. hereby requests that its acceleration request dated July 9, 2019 be withdrawn.
Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 with any questions.
Very truly yours,
TONIX PHARMACEUTICALS HOLDINGS
CORP.
By:
/s/
Bradley Saenger
Name:
Bradley Saenger
Title:
Chief Financial Officer